Sander van Deventer is a co-founder of VectorY Therapeutics and has been the President of VectorY’s Research and Development since November 2024. Dr. van Deventer has 25 years of experience in drug development and has played a critical role in the development of the first commercial monoclonal antibody (Remicade) as well as the first gene therapy to be granted market authorization in the Western world (Glybera).

Dr. van Deventer was previously the Chief Executive Officer of VectorY Therapeutics. In 1998, Dr. van Deventer co-founded Amsterdam Molecular Therapeutics (AMT N.V.), currently uniQure N.V. (NASDAQ: QURE), an AAV-based gene therapy company, acting subsequently as CSO, CMO and CEO. He also served as CEO of Dezima which was sold to Amgen for $1bn. In 2017, he re-joined uniQure as its part-time CSO where he brought the hemophilia B and Huntington’s disease programs to clinical development. He served on the boards of Hookipa, Engene, Borean, Dezima, Argos, and the scientific advisory boards of Hookipa, Argos, Engene and Staten.

Dr. van Deventer holds an M.D. and Ph.D. in Internal Medicine and Gastroenterology from the University of Amsterdam. He is also a former professor of Experimental Medicine and Gastroenterology at the Amsterdam Academic Medical Center and of Translational Gastroenterology at the University of Leiden. He has authored over 80 book chapters, 600 peer-reviewed papers, organized international scientific conferences, and supervised more than 40 PhD students.